Pub Date : 2025-12-01Epub Date: 2024-12-20DOI: 10.1080/21645515.2024.2443281
Ning Sun, Rui Wei, Bochao Jia, Taiwei Lou, Zirong Li, Xiaowei Nie, Wenxiao Yu, Miaoran Wang, Qiuyan Li
Globally, there are over 3 million severe cases of influenza each year, leading to up to half a million deaths. This study provides a comprehensive analysis of the current status of children's influenza vaccine research over the past 20 years and explores potential future research trends, including improvements in vaccine coverage and strategies to address vaccine hesitancy. We extracted all research data on children's influenza vaccines from 2004 to 2024 using the Web of Science Core Collection (WOSCC). The contributions of various countries/regions, institutions, authors, and journals in this field were assessed, and research hotspots as well as promising future trends were predicted through keyword analysis using CiteSpace and VOSviewer. A total of 2,598 related publications from 2004 to 2024 were identified and collected for analysis. The United States (USA) and England emerged as the leading contributors with the highest number of published papers. AstraZeneca was identified as a key leader among research institutions, and Ambrose Christopher S was recognized as the most productive author in this field. The journals Vaccine and Human Vaccines & Immunotherapeutics stood out as the most prominent publications in this area. The keyword analysis highlighted that international research collaboration maybe a promising strategy for bridging global gaps; Addressing vaccine hesitancy could potentially increase vaccination coverage; Live attenuated vaccines, intranasal administration and universal vaccines are promising directions for future development. These insights highlight potential avenues for improving influenza vaccine coverage and inform strategies to mitigate vaccine hesitancy, crucial for protecting children and enhancing public health.
全球每年有300多万例严重流感病例,导致多达50万人死亡。本研究全面分析了过去20年来儿童流感疫苗研究的现状,并探讨了潜在的未来研究趋势,包括提高疫苗覆盖率和解决疫苗犹豫问题的策略。我们使用Web of Science Core Collection (WOSCC)提取了2004 - 2024年关于儿童流感疫苗的所有研究数据。通过CiteSpace和VOSviewer的关键词分析,评估了各国/地区、机构、作者和期刊在该领域的贡献,预测了该领域的研究热点和未来发展趋势。从2004年到2024年,共收集了2598份相关出版物进行分析。美国(USA)和英国成为发表论文数量最多的主要贡献者。阿斯利康被认为是研究机构中的关键领导者,Ambrose Christopher S被认为是该领域最具生产力的作者。《疫苗》和《人类疫苗与免疫疗法》杂志是这一领域最突出的出版物。关键词分析强调,国际研究合作可能是弥合全球差距的一个有希望的战略;解决疫苗犹豫问题可能会增加疫苗接种覆盖率;减毒活疫苗、鼻内给药和通用疫苗是未来的发展方向。这些见解突出了改善流感疫苗覆盖率的潜在途径,并为减轻疫苗犹豫的战略提供信息,这对保护儿童和加强公共卫生至关重要。
{"title":"Research trends and key contributors in studies on influenza vaccines for children: A 20-year bibliometric analysis.","authors":"Ning Sun, Rui Wei, Bochao Jia, Taiwei Lou, Zirong Li, Xiaowei Nie, Wenxiao Yu, Miaoran Wang, Qiuyan Li","doi":"10.1080/21645515.2024.2443281","DOIUrl":"https://doi.org/10.1080/21645515.2024.2443281","url":null,"abstract":"<p><p>Globally, there are over 3 million severe cases of influenza each year, leading to up to half a million deaths. This study provides a comprehensive analysis of the current status of children's influenza vaccine research over the past 20 years and explores potential future research trends, including improvements in vaccine coverage and strategies to address vaccine hesitancy. We extracted all research data on children's influenza vaccines from 2004 to 2024 using the Web of Science Core Collection (WOSCC). The contributions of various countries/regions, institutions, authors, and journals in this field were assessed, and research hotspots as well as promising future trends were predicted through keyword analysis using CiteSpace and VOSviewer. A total of 2,598 related publications from 2004 to 2024 were identified and collected for analysis. The United States (USA) and England emerged as the leading contributors with the highest number of published papers. AstraZeneca was identified as a key leader among research institutions, and Ambrose Christopher S was recognized as the most productive author in this field. The journals <i>Vaccine</i> and <i>Human Vaccines & Immunotherapeutics</i> stood out as the most prominent publications in this area. The keyword analysis highlighted that international research collaboration maybe a promising strategy for bridging global gaps; Addressing vaccine hesitancy could potentially increase vaccination coverage; Live attenuated vaccines, intranasal administration and universal vaccines are promising directions for future development. These insights highlight potential avenues for improving influenza vaccine coverage and inform strategies to mitigate vaccine hesitancy, crucial for protecting children and enhancing public health.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2443281"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-21DOI: 10.1080/21645515.2025.2454073
Beata Mayer, Pavel Babál, Lucia Krivošíková
Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs. Histopathological examination and direct immunofluorescence showed characteristic features of SCLE. The patient was treated with oral prednisone 40 mg daily and topical corticosteroids. In 2 weeks, her rash had cleared up significantly and her pruritus had disappeared. SCLE is an infrequent but recognized immune-related adverse event linked to pembrolizumab treatment.
{"title":"Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review.","authors":"Beata Mayer, Pavel Babál, Lucia Krivošíková","doi":"10.1080/21645515.2025.2454073","DOIUrl":"https://doi.org/10.1080/21645515.2025.2454073","url":null,"abstract":"<p><p>Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs. Histopathological examination and direct immunofluorescence showed characteristic features of SCLE. The patient was treated with oral prednisone 40 mg daily and topical corticosteroids. In 2 weeks, her rash had cleared up significantly and her pruritus had disappeared. SCLE is an infrequent but recognized immune-related adverse event linked to pembrolizumab treatment.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454073"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2024-12-19DOI: 10.1080/21645515.2024.2439590
Rana H Shembesh, Mohammed S Beshr, Mariam M ALTarhouni
We aim to identify Libyans' knowledge, attitudes, and acceptance regarding the COVID-19 vaccine. A cross-sectional survey was electronically distributed to the Libyan population aged 18 and older between May and September 2023. The questionnaire had three sections: socio-demographics, COVID-19 vaccination and infection, and knowledge and attitudes toward the COVID-19 vaccine. The chi-square test was used to assess the associations. A total of 1,043 respondents completed the questionnaire. Of these, 590 (56.6%) were vaccinated, and 453 (43.4%) were unvaccinated. Only age, educational level, employment status, history of COVID-19 infection, and source of information had a significant association with vaccination status; all shared a p-value <.05. However, Monthly income did not. Regarding knowledge, 63.7% agreed that vaccines in general are an effective way to prevent and control infectious diseases, and 76.6% agreed that they can prevent disease and mortality. However, regarding COVID-19 vaccine, 48.4% agreed that the benefits outweigh the risks. Regarding COVID-19 safety, 40.8% responded that COVID-19 vaccines are only slightly safe or not safe at all. COVID-19 vaccine acceptance was at 57.2%, and only age and source of information were significantly associated. Those who held favorable views were more likely to accept the vaccine, while those who had concerns about safety were more vaccine hesitant. There is a gap between the perception of the COVID-19 vaccine compared to other vaccines among Libyans. Our study revealed that 57.2% of Libyans accept the COVID-19 vaccine. However, only 34% of the Libyan population is vaccinated. A comprehensive health policy is needed.
{"title":"COVID-19 vaccine knowledge and acceptance among the Libyan population: A cross-sectional study.","authors":"Rana H Shembesh, Mohammed S Beshr, Mariam M ALTarhouni","doi":"10.1080/21645515.2024.2439590","DOIUrl":"10.1080/21645515.2024.2439590","url":null,"abstract":"<p><p>We aim to identify Libyans' knowledge, attitudes, and acceptance regarding the COVID-19 vaccine. A cross-sectional survey was electronically distributed to the Libyan population aged 18 and older between May and September 2023. The questionnaire had three sections: socio-demographics, COVID-19 vaccination and infection, and knowledge and attitudes toward the COVID-19 vaccine. The chi-square test was used to assess the associations. A total of 1,043 respondents completed the questionnaire. Of these, 590 (56.6%) were vaccinated, and 453 (43.4%) were unvaccinated. Only age, educational level, employment status, history of COVID-19 infection, and source of information had a significant association with vaccination status; all shared a p-value <.05. However, Monthly income did not. Regarding knowledge, 63.7% agreed that vaccines in general are an effective way to prevent and control infectious diseases, and 76.6% agreed that they can prevent disease and mortality. However, regarding COVID-19 vaccine, 48.4% agreed that the benefits outweigh the risks. Regarding COVID-19 safety, 40.8% responded that COVID-19 vaccines are only slightly safe or not safe at all. COVID-19 vaccine acceptance was at 57.2%, and only age and source of information were significantly associated. Those who held favorable views were more likely to accept the vaccine, while those who had concerns about safety were more vaccine hesitant. There is a gap between the perception of the COVID-19 vaccine compared to other vaccines among Libyans. Our study revealed that 57.2% of Libyans accept the COVID-19 vaccine. However, only 34% of the Libyan population is vaccinated. A comprehensive health policy is needed.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2439590"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and pelvic bones. Recently, many researchers have confirmed that biological therapy is effective for AS patients, which provides a new perspective for the treatment of AS. This study aimed to evaluate the characteristics of scientific research on AS and biological therapy worldwide and investigate research hotspots and the direction of future trends. Global literature on AS and biological therapy published from 2004 to 2023 was searched in the Web of Science, Scopus, and PubMed databases. Visualization and bibliometric analysis were carried out using the VOSviewer and CiteSpace software with the retrieved data regarding countries, institutions, journals, authors, and keywords. A total of 2,243 related articles were included, showing that the number of articles in this field has increased annually. The highest number of articles were from the USA (24.39%), followed by Italy (14.36%), England (12.19%), Germany (10.66%), and Spain (7.86%). Braun J was the most prolific author, with a h-index of 16. The institution with the most articles was Charite Universitatsmedizin Berlin, and the Rheumatology journal had the highest number of publications. "janus kinase inhibitor" and "secukinumab" displayed a notable citation burst in recent years, indicating IL-17i and JAKi are research hotspots. More and more attention has been paid to the association between AS and biological therapy in the past two decades. The USA plays a leading role, and China has made remarkable progress. This study has provided a valuable reference for future research in this field.
强直性脊柱炎(AS)是一种慢性炎症性疾病,主要影响脊柱和骨盆骨。近年来,许多研究者证实生物疗法对AS患者有效,这为AS的治疗提供了新的视角。本研究旨在评价全球AS及生物治疗的科学研究特点,探讨研究热点及未来发展趋势。在Web of Science、Scopus和PubMed数据库中检索了2004年至2023年发表的关于AS和生物治疗的全球文献。利用VOSviewer和CiteSpace软件对检索到的国家、机构、期刊、作者和关键词等数据进行可视化和文献计量分析。共收录了2243篇相关文章,表明该领域的文章数量每年都在增加。文章数量最多的是美国(24.39%),其次是意大利(14.36%)、英国(12.19%)、德国(10.66%)和西班牙(7.86%)。博朗J是最多产的作者,h指数为16。发表文章最多的机构是柏林的Charite Universitatsmedizin Berlin,而风湿病学期刊的发表数量最多。“janus kinase inhibitor”和“secukinumab”近年来出现了明显的引用爆发,表明IL-17i和JAKi是研究热点。近二十年来,人们越来越关注AS与生物治疗的关系。美国发挥了主导作用,中国取得了显著进步。本研究为今后该领域的研究提供了有价值的参考。
{"title":"Global research trends in biological therapy for ankylosing spondylitis: A comprehensive visualization and bibliometric study (2004-2023).","authors":"Weiliang He, Haicheng Yang, Xuanzhe Yang, JinFeng Huang, Zixiang Wu","doi":"10.1080/21645515.2024.2445900","DOIUrl":"10.1080/21645515.2024.2445900","url":null,"abstract":"<p><p>Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and pelvic bones. Recently, many researchers have confirmed that biological therapy is effective for AS patients, which provides a new perspective for the treatment of AS. This study aimed to evaluate the characteristics of scientific research on AS and biological therapy worldwide and investigate research hotspots and the direction of future trends. Global literature on AS and biological therapy published from 2004 to 2023 was searched in the Web of Science, Scopus, and PubMed databases. Visualization and bibliometric analysis were carried out using the VOSviewer and CiteSpace software with the retrieved data regarding countries, institutions, journals, authors, and keywords. A total of 2,243 related articles were included, showing that the number of articles in this field has increased annually. The highest number of articles were from the USA (24.39%), followed by Italy (14.36%), England (12.19%), Germany (10.66%), and Spain (7.86%). Braun J was the most prolific author, with a h-index of 16. The institution with the most articles was Charite Universitatsmedizin Berlin, and the Rheumatology journal had the highest number of publications. \"janus kinase inhibitor\" and \"secukinumab\" displayed a notable citation burst in recent years, indicating IL-17i and JAKi are research hotspots. More and more attention has been paid to the association between AS and biological therapy in the past two decades. The USA plays a leading role, and China has made remarkable progress. This study has provided a valuable reference for future research in this field.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2445900"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This bibliometric and visualization study provides a comprehensive analysis of global research hotspots and trends in DNA vaccine research from 2014 to 2024. By employing data sourced from the Web of Science Core Collection, we identified a total of 3,600 articles. Our analysis reveals a declining trend in annual publications. Active countries, institutions, journals, and authors were identified, with China, the Pasteur Network, the Vaccine Journal, and David B Weiner being the most prolific contributors. Keywords cluster analysis distinguished four major research directions: infectious disease and immunity, viral challenge and vaccine development, optimization of DNA vaccine delivery systems, and cancer and immunotherapy research. The literature co-citation analysis revealed four major research hotspots, including DNA vaccines for Zika virus, human papillomavirus (HPV), and COVID-19, as well as safety, efficacy, and immunogenicity studies of DNA vaccines. Concurrently, the burst citation analysis identified emerging themes, including the development of DNA vaccines for COVID-19, Ebola, and MERS-CoV, as well as innovations in antigen design and delivery technologies. This study offers valuable insights into the evolution and future directions of DNA vaccine research, emphasizing its importance for global public health and the potential to address current and future health challenges.
{"title":"Global research hotspots and trends in DNA vaccine research: A bibliometric and visualization study from 2014 to 2024.","authors":"Juan Zhang, Haiguo Zhang, Cuicui Yao, Lihua Gu, Shasha Dong, Yamei Wu, Lele Miao","doi":"10.1080/21645515.2025.2457189","DOIUrl":"10.1080/21645515.2025.2457189","url":null,"abstract":"<p><p>This bibliometric and visualization study provides a comprehensive analysis of global research hotspots and trends in DNA vaccine research from 2014 to 2024. By employing data sourced from the Web of Science Core Collection, we identified a total of 3,600 articles. Our analysis reveals a declining trend in annual publications. Active countries, institutions, journals, and authors were identified, with China, the Pasteur Network, the <i>Vaccine</i> Journal, and David B Weiner being the most prolific contributors. Keywords cluster analysis distinguished four major research directions: infectious disease and immunity, viral challenge and vaccine development, optimization of DNA vaccine delivery systems, and cancer and immunotherapy research. The literature co-citation analysis revealed four major research hotspots, including DNA vaccines for Zika virus, human papillomavirus (HPV), and COVID-19, as well as safety, efficacy, and immunogenicity studies of DNA vaccines. Concurrently, the burst citation analysis identified emerging themes, including the development of DNA vaccines for COVID-19, Ebola, and MERS-CoV, as well as innovations in antigen design and delivery technologies. This study offers valuable insights into the evolution and future directions of DNA vaccine research, emphasizing its importance for global public health and the potential to address current and future health challenges.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2457189"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-30DOI: 10.1080/21645515.2025.2458936
Saber Imani, Parham Jabbarzadeh Kaboli, Ali Babaeizad, Mazaher Maghsoudloo
Although neo-antigen mRNA vaccines are promising for personalized cancer therapy, their effectiveness is often limited by the immunosuppressive tumor microenvironment (TME). The adenosine A2A receptor (A2AR) inhibits dendritic cell (DC) function and weakens antitumor T cell responses through hypoxia-driven mechanisms within the TME. This review explores a novel strategy combining neo-antigen mRNA vaccines with A2AR antagonists (A2ARi). By targeting A2AR, this approach reduces TME-induced immunosuppression, enhances DC activation, and improves neo-antigen presentation. The review also discusses lipid nanoparticles (LNPs) to co-deliver A2ARi and mRNA vaccines, optimizing their effectiveness. The integration of neo-antigen mRNA-LNPs with A2ARi modulation offers a promising strategy to overcome immunosuppression, stimulate DC activation, and achieve precise anti-tumor responses with minimal off-target effects. This synergy represents significant progress in cancer immunotherapy, advancing the potential for personalized neoantigen therapies.
{"title":"Neoantigen mRNA vaccines and A<sub>2</sub>A receptor antagonism: A strategy to enhance T cell immunity.","authors":"Saber Imani, Parham Jabbarzadeh Kaboli, Ali Babaeizad, Mazaher Maghsoudloo","doi":"10.1080/21645515.2025.2458936","DOIUrl":"10.1080/21645515.2025.2458936","url":null,"abstract":"<p><p>Although neo-antigen mRNA vaccines are promising for personalized cancer therapy, their effectiveness is often limited by the immunosuppressive tumor microenvironment (TME). The adenosine A<sub>2</sub>A receptor (A<sub>2</sub>AR) inhibits dendritic cell (DC) function and weakens antitumor T cell responses through hypoxia-driven mechanisms within the TME. This review explores a novel strategy combining neo-antigen mRNA vaccines with A<sub>2</sub>AR antagonists (A<sub>2</sub>ARi). By targeting A<sub>2</sub>AR, this approach reduces TME-induced immunosuppression, enhances DC activation, and improves neo-antigen presentation. The review also discusses lipid nanoparticles (LNPs) to co-deliver A<sub>2</sub>ARi and mRNA vaccines, optimizing their effectiveness. The integration of neo-antigen mRNA-LNPs with A<sub>2</sub>ARi modulation offers a promising strategy to overcome immunosuppression, stimulate DC activation, and achieve precise anti-tumor responses with minimal off-target effects. This synergy represents significant progress in cancer immunotherapy, advancing the potential for personalized neoantigen therapies.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2458936"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-09DOI: 10.1080/21645515.2024.2442508
Jiachen Zhang, Yani Zhang, Litao Zhang, Jiaxing Wang, Xinheng Qu, Mu Li, Ruochen Zhang, Bo Zhang, Yuqing Zhang, Jianping Zhou
The objective of this study is to gain insight into the current research frontiers, hotspots, and development trends in the field of immunization programs for women and children, and to provide scientific guidance and reference for follow-up research. Based on all the original research papers related to the research on immunization programs for women and children in the Web of Science Core Collection (WoSCC) database, bibliometric studies and visual analysis were carried out to explore the research frontiers, hotspots and development trends, and to analyze the risk factors affecting the vaccination coverage of immunization programs for women and children. Eight hundred forty-three papers obtained from 1,552 institutions in 96 countries/regions from January 1950 to August 2024, coauthored by 4,343 authors. With the largest number of papers published in the United States (408), Centers for Disease Control & Prevention - USA (169), Stokley S (15), and Pediatrics (143). The research frontiers of this discipline area mainly involve risk factors affecting the vaccination coverage of immunization programs for women and children, epidemiological surveillance, intervention research, changes in medical burden, adverse reactions, and vaccine development. Research hotspots mainly include measles, vaccine hesitancy, human papillomavirus, coverage, and pregnant women. The findings of the study informed policymakers, public health experts and researchers about the potential for modifying and improving policy systems and interventions related to the immunization programs for women and children. This had important implications for digital transformation and innovative research in health care providers' clinical practice for the immunization programs for women and children.
本研究旨在了解当前妇女儿童免疫规划领域的研究前沿、热点和发展趋势,为后续研究提供科学指导和参考。基于Web of Science Core Collection (WoSCC)数据库中所有与妇女儿童免疫规划研究相关的原创研究论文,采用文献计量学和可视化分析的方法,探索研究前沿、热点和发展趋势,分析影响妇女儿童免疫规划疫苗接种率的危险因素。1950年1月至2024年8月,在96个国家/地区的1552个机构共发表论文843篇,作者4343人。发表论文最多的是美国(408篇),其次是美国疾病控制与预防中心(169篇)、Stokley S(15篇)和Pediatrics(143篇)。本学科的研究前沿主要涉及影响妇女儿童免疫规划接种覆盖率的危险因素、流行病学监测、干预研究、医疗负担变化、不良反应、疫苗研制等。研究热点主要包括麻疹、疫苗犹豫、人乳头瘤病毒、覆盖率、孕妇等。这项研究的结果使政策制定者、公共卫生专家和研究人员了解了修改和改进与妇女和儿童免疫规划有关的政策体系和干预措施的潜力。这对医疗保健提供者在妇女和儿童免疫规划的临床实践中的数字化转型和创新研究具有重要意义。
{"title":"Visual analysis of the research frontiers, hotspots and development trends of immunization programs for women and children.","authors":"Jiachen Zhang, Yani Zhang, Litao Zhang, Jiaxing Wang, Xinheng Qu, Mu Li, Ruochen Zhang, Bo Zhang, Yuqing Zhang, Jianping Zhou","doi":"10.1080/21645515.2024.2442508","DOIUrl":"10.1080/21645515.2024.2442508","url":null,"abstract":"<p><p>The objective of this study is to gain insight into the current research frontiers, hotspots, and development trends in the field of immunization programs for women and children, and to provide scientific guidance and reference for follow-up research. Based on all the original research papers related to the research on immunization programs for women and children in the Web of Science Core Collection (WoSCC) database, bibliometric studies and visual analysis were carried out to explore the research frontiers, hotspots and development trends, and to analyze the risk factors affecting the vaccination coverage of immunization programs for women and children. Eight hundred forty-three papers obtained from 1,552 institutions in 96 countries/regions from January 1950 to August 2024, coauthored by 4,343 authors. With the largest number of papers published in the United States (408), Centers for Disease Control & Prevention - USA (169), Stokley S (15), and Pediatrics (143). The research frontiers of this discipline area mainly involve risk factors affecting the vaccination coverage of immunization programs for women and children, epidemiological surveillance, intervention research, changes in medical burden, adverse reactions, and vaccine development. Research hotspots mainly include measles, vaccine hesitancy, human papillomavirus, coverage, and pregnant women. The findings of the study informed policymakers, public health experts and researchers about the potential for modifying and improving policy systems and interventions related to the immunization programs for women and children. This had important implications for digital transformation and innovative research in health care providers' clinical practice for the immunization programs for women and children.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2442508"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-21DOI: 10.1080/21645515.2024.2448023
Li Li, Jingyi Xu, Dongkun Zhang, Jianlin Cai, Zhen Li, Xiaohui Zhang, Shuping Li
We report and analyze a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Chaoyang District of Beijing and to evaluate the causality between the disease and vaccination. Based on the professional branch of this case, we organized a seminar and we invited specialists in vaccinology, epidemiology, dermatology, infectiology, and immunology to participate in the conference. Specialists evaluated the relevance and causality between the vaccination and disease. The clinical diagnosis of the adolescent was pilomatricoma after receiving recombinant hepatitis B vaccine (CHO cell) which could not be disregarded as an adverse reaction following immunization. Although rare, there is a possibility of developing pilomatricoma after vaccination. This suggests that the implementation process of vaccination should be standardized and that the injection site after vaccination should be nursed properly.
{"title":"Analysis of a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Beijing of China.","authors":"Li Li, Jingyi Xu, Dongkun Zhang, Jianlin Cai, Zhen Li, Xiaohui Zhang, Shuping Li","doi":"10.1080/21645515.2024.2448023","DOIUrl":"https://doi.org/10.1080/21645515.2024.2448023","url":null,"abstract":"<p><p>We report and analyze a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Chaoyang District of Beijing and to evaluate the causality between the disease and vaccination. Based on the professional branch of this case, we organized a seminar and we invited specialists in vaccinology, epidemiology, dermatology, infectiology, and immunology to participate in the conference. Specialists evaluated the relevance and causality between the vaccination and disease. The clinical diagnosis of the adolescent was pilomatricoma after receiving recombinant hepatitis B vaccine (CHO cell) which could not be disregarded as an adverse reaction following immunization. Although rare, there is a possibility of developing pilomatricoma after vaccination. This suggests that the implementation process of vaccination should be standardized and that the injection site after vaccination should be nursed properly.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2448023"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-30DOI: 10.1080/21645515.2024.2440203
Siqi Zhang, Lina Miao, Xiaoxia Tian, Bingxu Yang, Baoping Luo
The emergence of immuno-oncology (IO) has led to revolutionary changes in the field of cancer treatment. Despite notable advancements in this field, a thorough exploration of its full depth and extent has yet to be performed. This study provides a comprehensive overview of publications pertaining to IO. Publications on IO from 2014 to 2023 were retrieved by searching the Web of Science Core Collection database (WoSCC). VOSviewer software and Citespace software were used for the visualized analysis. A total of 1,874 articles have been published in the IO domain. The number of publications and citations has been increasing annually. This study also examines the primary research directions within the field of IO. In conclusion, this study offers a comprehensive overview of the opportunities and challenges associated with IO, illuminating the current status of research and indicating potential future trajectories in this rapidly progressing field. This study provides a comprehensive survey of the current research status and hot spots within the field of IO. It will assist researchers in comprehending the current research emphasis and development trends in this field and offers guidance for future research directions.
{"title":"Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023.","authors":"Siqi Zhang, Lina Miao, Xiaoxia Tian, Bingxu Yang, Baoping Luo","doi":"10.1080/21645515.2024.2440203","DOIUrl":"10.1080/21645515.2024.2440203","url":null,"abstract":"<p><p>The emergence of immuno-oncology (IO) has led to revolutionary changes in the field of cancer treatment. Despite notable advancements in this field, a thorough exploration of its full depth and extent has yet to be performed. This study provides a comprehensive overview of publications pertaining to IO. Publications on IO from 2014 to 2023 were retrieved by searching the Web of Science Core Collection database (WoSCC). VOSviewer software and Citespace software were used for the visualized analysis. A total of 1,874 articles have been published in the IO domain. The number of publications and citations has been increasing annually. This study also examines the primary research directions within the field of IO. In conclusion, this study offers a comprehensive overview of the opportunities and challenges associated with IO, illuminating the current status of research and indicating potential future trajectories in this rapidly progressing field. This study provides a comprehensive survey of the current research status and hot spots within the field of IO. It will assist researchers in comprehending the current research emphasis and development trends in this field and offers guidance for future research directions.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440203"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}